- Home
- Publications
- Publication Search
- Publication Details
Title
Role of taxanes in advanced prostate cancer
Authors
Keywords
Prostate cancer, Docetaxel, Cabazitaxel, Androgen deprivation therapy, AR splice variant
Journal
Clinical & Translational Oncology
Volume 18, Issue 10, Pages 972-980
Publisher
Springer Nature
Online
2016-02-08
DOI
10.1007/s12094-015-1480-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 783PPRELIMINARY RESULTS OF A PHASE II STUDY OF WEEKLY CABAZITAXEL IN "UNFIT" METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS PROGRESSING AFTER DOCETAXEL TREATMENT (SOGUG-CABASEM TRIAL)
- (2017) B. Pérez-Valderrama et al. ANNALS OF ONCOLOGY
- Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) C. Parker et al. ANNALS OF ONCOLOGY
- Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices
- (2015) Guru Sonpavde et al. Clinical Genitourinary Cancer
- Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer
- (2015) Francesca Maines et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies
- (2015) Nader Al Nakouzi et al. EUROPEAN UROLOGY
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- SEOM Clinical guidelines for the treatment of metastatic prostate cancer
- (2014) J. Cassinello et al. Clinical & Translational Oncology
- Response to Subsequent Docetaxel in a Patient Cohort With Metastatic Castration-Resistant Prostate Cancer After Abiraterone Acetate Treatment
- (2014) Rahul Aggarwal et al. Clinical Genitourinary Cancer
- Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme
- (2014) Axel Heidenreich et al. EUROPEAN JOURNAL OF CANCER
- The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
- (2014) Michael T. Schweizer et al. EUROPEAN UROLOGY
- Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program
- (2014) Daniel Castellano et al. Expert Opinion On Drug Safety
- CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel
- (2014) Michel D. Wissing et al. INTERNATIONAL JOURNAL OF CANCER
- Neuroendocrine Prostate Cancer After Hormonal Therapy: Knowing Is Half the Battle
- (2014) Scott T. Tagawa JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer
- (2014) Arun A. Azad et al. PROSTATE
- Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
- (2013) A. Bahl et al. ANNALS OF ONCOLOGY
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- Taxane Mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer
- (2013) John M. Fitzpatrick et al. EUROPEAN UROLOGY
- Visceral Disease in Castration-resistant Prostate Cancer
- (2013) Carmel J. Pezaro et al. EUROPEAN UROLOGY
- Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents
- (2013) Carmel J. Pezaro et al. EUROPEAN UROLOGY
- 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
- (2013) Pirkko-Liisa Kellokumpu-Lehtinen et al. LANCET ONCOLOGY
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
- (2013) Gwenaelle Gravis et al. LANCET ONCOLOGY
- Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
- (2012) J. Mezynski et al. ANNALS OF ONCOLOGY
- Adaptation or selection—mechanisms of castration-resistant prostate cancer
- (2012) Yang Zong et al. Nature Reviews Urology
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
- (2011) H. Beltran et al. Cancer Discovery
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy Before Radical Prostatectomy for Patients With High Risk Localized Prostate Cancer
- (2008) Kim N. Chi et al. JOURNAL OF UROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now